OSW OneSpaWorld Holdings Limited
OneSpaWorld Holdings Limited operates health and wellness centers onboard cruise ships and at destination resorts in the United States and internationally. It offers massage and body care services and therapies, and aesthetics treatments; medi-spa services; and acupuncture, electric stimulation acupuncture, LED therapy, cupping, posture and gait analysis, and therapy for recovery. The company also provides fitness centers, and personalized training services and consultation; personal nutritional and dietary consultation, weight management, nutrition coaching and detoxification; hot and cold hydro-therapies and related amenities, such as thermal loungers, infrared saunas, snow rooms, laconiums, caldarium chambers, and hammams, as well as cold plunge pools, large therapeutic jacuzzis, and rooms surrounding occupants with layers of body cleansing salt crystals. In addition, the company offers products under the ELEMIS, Grown Alchemist, Kerastase, Keratin Complex, Thermage, Dysport, GoodFeet arch supports, Hyperice, and Megawhite teeth whitening brands. OneSpaWorld Holdings Limited was founded in 2017 and is based in Nassau, Bahamas.…
Industry Peers
LeisureKey Statistics
About OneSpaWorld Holdings (NASDAQ: OSW)
›
OneSpaWorld Holdings (NASDAQ: OSW) is listed on Nasdaq, where its shares trade in USD. It belongs to the Leisure industry, part of the Consumer Cyclical sector, and reports about 5,395 employees.
The shares were at 30.68 USD on 19 November 2026, up 38.9% over 52 weeks. Its 52-week range is 19.06 USD to 33.05 USD: the price is 7.2% below the high and 61.0% above the low.
At a market capitalisation of 3.07B USD, it trades at 37.0 times trailing earnings and 23.2 times forward earnings. The median trailing P/E of its 17 largest Leisure peers is 21.0, a premium of 76% for OSW. It pays a dividend yielding 0.79% (it pays out 24% of its earnings), against a median of 2.36% among the dividend payers in that peer group.
OneSpaWorld Holdings reports return on equity of 13.2%, an operating margin of 9.7% and revenue up 7.0% year over year.
Its debt exceeds its cash by 46.41M USD, a debt-to-equity ratio of 0.17. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 5 analysts cover the stock; their mean price target of 33.00 USD is 7.6% above the current price. The next earnings report is expected on 17 February 2027.